Latest News for: nci

Edit

Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma (NCI - National Cancer Institute)

Public Technologies 04 Nov 2021
The findings, published November 4, 2021, in Cancer Cell, come from a new analysis by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, of a previously conducted phase 3 clinical trial ... Staudt, M.D., Ph.D., chief of the Lymphoid Malignancies Branch in the Cancer for Cancer Research at NCI.
Edit

BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual ...

Nasdaq Globe Newswire 20 Oct 2021
... models supporting the use of plinabulin in small cell lung cancer (SCLC) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held October 7-10, 2021.
Edit

Modi to inaugurate Vishram Sadan at NCI in AIIMS' Jhajjar campus

MENA FN 20 Oct 2021
(MENAFN - IANS) New Delhi, Oct 20 (IANS) Prime Minister Narendra Modi on Thursday will virtually inaugurate the Infosys Foundation Vishram Sadan at National Cancer Institute (NCI) in the Jhajjar campus of AIIMS-Delhi, officials said on... .
Edit

BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer (BeyondSpring Inc)

Public Technologies 20 Oct 2021
BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the presentation of preclinical data in patient-derived (PDX) cancer models supporting the use of plinabulin in small cell lung cancer (SCLC) at the 2021 AACR-NCI-EORTC ...
Edit

Rakovina Therapeutics Presents at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Nasdaq Globe Newswire 12 Oct 2021
Presentation highlights pre-clinical data from Rakovina Therapeutics’ novel kt-3000 series dual PARP-HDAC inhibitors. Presentation highlights pre-clinical data from Rakovina Therapeutics’ novel kt-3000 series dual PARP-HDAC inhibitors ... .
Edit

Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program

PR Newswire 12 Oct 2021
"This grant from the NCI/NIH allows us to further characterize the in vitro activity and in vivo safety and activity of ST316, which will enable us to accelerate the advancement of this program toward the clinic.".
Edit

Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of ...

The Salamanca Press 12 Oct 2021
"This grant from the NCI/NIH allows us to further characterize the in vitro activity and in vivo safety and activity of ST316, which will enable us to accelerate the advancement of this program toward the clinic.".
Edit

Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International ...

The Associated Press 11 Oct 2021
... three key preclinical datasets highlighting the potential of its lead product candidate, IMM-1-104, were presented at the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics that took place virtually from October 7-10, 2021.ADVERTISEMENT.
Edit

Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly ...

Nasdaq Globe Newswire 08 Oct 2021
Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor ... .
×